Millennium Pharmaceuticals, Inc.
40 Landsdowne Street Cambridge, MA 02139
Phone: (617) 679-7000
Web Site: www.mlnm.com
Industry: Drugs Sector: Healthcare
Employees: 1,142
Stock Symbol: MLNM

Business Summary: Millennium Pharmaceuticals, Inc., a biopharmaceutical company, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on discovering, developing and commercializing innovative products in disease areas with unmet medical needs. It currently commercializes VELCADE for Injection, for the treatment of patients with relapsed multiple myeloma. It has a development pipeline of seven clinical and preclinical product candidates in its therapeutic focus areas of cancer and inflammation and has an oncology-focused discovery organization. Strategic business relationships are a key component of its business. The Company sells VELCADE in the United States directly through its oncology sales force. VELCADE is sold in the European Union and other approved areas outside of the United States by its collaborator Ortho Biotech Products, L.P., or Ortho Biotech, a member of the Johnson & Johnson Family of Companies. VELCADE, the first of a new class of medicines called proteasome inhibitors, was the first treatment in more than a decade to be approved in the United States for patients with multiple myeloma. In addition to its ongoing clinical trials of VELCADE, the Company has a number of drug candidates in clinical and late preclinical development. The Company has built a cancer specialized sales force geographically dispersed across the United States. The Company owns issued United States patents, granted foreign patents and pending United States and foreign applications for VELCADE. It owns issued United States patents, granted foreign patents and pending United States and foreign applications for INTEGRILIN. The Company also owns issued patents and/or pending United States and foreign patent applications related to MLN02, MLN1202 and MLN3897. The Company currently owns a number of trademarks and servicemarks including: Millennium, the Millennium M logo and design, Transcending the Limits of Medicine, VELCADE, INTEGRILIN and Breakthrough Science. Regulation by governmental authorities in the United States and other countries is a major factor in the manufacture and marketing of its products and in ongoing research and product development activities. All of the Company's products require regulatory approval by governmental agencies prior to commercialization. In particular, its products are subject to rigorous preclinical and clinical testing and other premarket approval requirements by the FDA and regulatory authorities in other countries. As of February 28, 2006, Millennium had approximately 1,142 full-time employees. Officers: Deborah Dunsire, M.D. , CEO